日本人肥満前または肥満の2型糖尿病患者を対象としたMEDI0382の安全性および忍容性に関する研究

基本情報

NCT ID

NCT03645421

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

61

治験依頼者名

AstraZeneca

概要

This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese subjects. The study D5674C00001 can be conducted with a reasonable expectation of safety and tolerability in Japanese T2DM patients. The design of this study has taken into account the known benefits and risks of GLP-1 receptor agonists and glucagon receptor agonists as well as the translatable effects observed in nonclinical studies of MEDI0382.

対象疾患

介入

依頼者（Sponsor）